ImCheck Therapeutics (private company)
See something wrong or missing? Let us know
Offices:Marseille
Industry:BiotechHealth servicesPharma
Business model:B2B
ImCheck Therapeutics is a developing novel therapeutics that target members of the butyrophilin (BTN) super-family of checkpoint molecules.
values in USD
Investments 102.3MM&A 1.173B
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Companies with similar profile to ImCheck Therapeutics
| Name | Criteria | |
|---|---|---|
![]() |
AbolerIS Pharma
70%
|
|
![]() |
Acesion Pharma
70%
|
|
![]() |
Citryll
70%
|
|
![]() |
NMD Pharma
70%
|
|
![]() |
Sanifit Therapeutics
70%
|
|
![]() |
Synklino
70%
|
|
![]() |
Theolytics
70%
|
|
![]() |
Cytoki Pharma
70%
|
|
![]() |
Causaly
70%
|
|
![]() |
Cardior Pharmaceuticals
70%
|
|






Belgium
Austria
Switzerland
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
Sweden
Ireland
Italy
Portugal